SEC Form 4 · accession 0001213900-26-080525
Jasper Therapeutics, Inc. · JSPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew E Ros
Officer — Chief Operating Officer
Period of report
Jul 20, 2026
Accepted (ET)
Jul 22, 2026 · 7:10 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001788028
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Voting Convertible Preferred StockF1,F2 | — | Jul 20, 2026 | P | 881 | A | — | — | Voting Common Stock | 53,741 | 881 | D |
Explanation of responses
- F1On July 16, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026.
- F2On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock ("Voting Common Stock"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date.